Expiring federal contract
36C24525C0015 — Mystic Ventures Group LLC
Department of Veterans Affairs
- Contract / PIID
- 36C24525C0015
- Incumbent
- Mystic Ventures Group LLC
- Incumbent UEI
- RWZAYJEKA5D5
- Current end date
- September 30, 2027
- Potential total value
- $561,685
- Obligated
- $561,685
- NAICS
- 325412 — Pharmaceutical Preparation Manufacturing
- PSC
- 6505 — DRUGS AND BIOLOGICALS
- Set-aside
- Not stated
- Start date
- October 1, 2024
- Place of performance
- GA
- Award type
- DEFINITIVE CONTRACT
Source: USASpending.gov award record, last checked November 19, 2026. Place of performance as reported by USASpending.
What the contract covers
RADIOPHARMACUETICALS
Likely rebid window (estimate)
- Sources Sought / RFI: about Sep 2026 – Mar 2027 (6–12 months before the end date)
- RFP: about May 2027 – Jul 2027 (2–4 months before the end date)
Now inside the estimated Sources Sought / RFI window.
Estimated from the current end date using typical federal recompete timing. Agencies set their own schedules, and contracts are often extended. This is not a published solicitation date.
Track this recompete free
- Change history: no changes recorded since Mindy began tracking this contract.
- Alerts: get an email when the end date moves or the follow-on is posted.
- Contacts: the buying office and small-business contacts for this agency.
Other contracts expiring at Department of Veterans Affairs (NAICS 325412)
- 36C24126F0039 — Medi-physics, INC. · ends November 21, 2026 · $100K
- 36C25026N0181 — Schaaf Drugs, LLC · ends November 22, 2026 · $681K
- 36C24626N0323 — Cardinal Health 414, LLC · ends November 30, 2026 · $323K
- 36C25226P0101 — Petnet Solutions, INC. · ends November 30, 2026 · $110K
- 36C26023P0532 — Cardinal Health 414, LLC · ends November 30, 2026 · $337K
- 36C26224P0297 — Rls (USA) INC. · ends November 30, 2026 · $1.1M
- 36C26226N0112 — Novartis Pharmaceuticals Corporation · ends November 30, 2026 · $4.3M
- 36C26227N0156 — Novartis Pharmaceuticals Corporation · ends November 30, 2026 · $769K
- 36C24726F0053 — Exelan Pharmaceuticals INC · ends December 7, 2026 · $4.8M
- 36C24126P0074 — Trillamed LLC · ends December 10, 2026 · $927K